Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Outlook Therapeutics Inc (OTLKW)

Outlook Therapeutics Inc (OTLKW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Outlook Therapeutics® Streamlines Operations GlobeNewswire - Fri Dec 13, 3:30PM CST

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD GlobeNewswire - Wed Dec 4, 7:05AM CST

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces Executive Leadership Transition GlobeNewswire - Tue Dec 3, 3:30PM CST

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial GlobeNewswire - Wed Nov 27, 5:50AM CST

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference GlobeNewswire - Wed Nov 6, 7:05AM CST

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment GlobeNewswire - Thu Oct 17, 8:00AM CDT

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones Globe Newswire - Wed Aug 10, 2022

Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference Globe Newswire - Thu Aug 4, 2022

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note Globe Newswire - Tue Jul 5, 2022

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010 Globe Newswire - Tue Jun 14, 2022

Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug...

OTLKW : 0.03 (-1.96%)
OTLK : 1.4400 (+3.60%)

Barchart Exclusives

Elon Musk Didn't Expect Tesla or SpaceX to be Succesful, But He Did It Because They "Were Important Enough to do Anyway" Barchart - 1 hour ago
In a reflection on his entrepreneurial journey, tech magnate Elon Musk offered a glimpse into the mindset that led him to launch two of the world’s most groundbreaking ventures: Tesla and SpaceX. Speaking on his early years of founding these companies, Musk said, “I always have optimism, but I’m realistic.... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot